Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2013 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013

Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year Fourth quarter net sales reached USD 14.8 billion (0%, +2% cc); full year...
January 22, 2013 01:44 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe

Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable[1] MenB disease is associated with a high human...
December 16, 2012 16:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder

As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease[1] In the Phase III trial, most patients...
December 10, 2012 18:15 ET | Source: NOVARTIS FINANCE S.A.

Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage

Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years COMFORT-II follow-up results show Jakavi may...
December 10, 2012 16:30 ET | Source: NOVARTIS FINANCE S.A.

Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®

Both newly diagnosed patients and those switching to Tasigna after long-term treatment with Glivec achieved deeper molecular response with Tasigna Data suggest correlation between early...
November 20, 2012 16:58 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza

Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years[1] Flucelvax is the only...
November 16, 2012 07:40 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives positive CHMP opinion for Bexsero®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe

Meningococcal serogroup B (MenB) disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities[1],[2] Upon approval, Bexsero will be the first and only...
November 09, 2012 08:10 ET | Source: NOVARTIS FINANCE S.A.

Italian authorities lift precautionary hold on Novartis seasonal influenza vaccines

Safety and efficacy of Agrippal® and Fluad® reaffirmed; over one million people vaccinated this season with no unexpected adverse events reported to date Temporary holds already lifted in Canada...
November 09, 2012 01:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis announces update to company's Board of Directors to take effect in February 2013

Basel, November 9, 2012 - Novartis announced today that Marjorie Yang has decided not to seek re-election to the Novartis Board of Directors at the Novartis Annual General Meeting in 2013. Ms. Yang...
November 08, 2012 01:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds

Pharmaceuticals Division growth over the next 5 years expected to be driven by portfolio of recently launched products Division had 7 blockbusters in portfolio in 2011 and expects to achieve 14...